This inventor holds 4 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignees: Otsuka Pharmaceutical Company, Limited, Gunma University. Active years: 2008-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tokushima, JP (2008 - 2011)
- Osaka, JP (2012)
Company Filing History:


Years Active: 2008-2026
Title: The Innovative Contributions of Shin Yazawa
Introduction
Shin Yazawa is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of cancer treatment through his innovative inventions. With a total of 4 patents, Yazawa's work focuses on developing effective chemotherapeutic agents with reduced side effects.
Latest Patents
Yazawa's latest patents include a cholestanol derivative designed for combined use as a cancer chemotherapeutic agent. This invention aims to provide a treatment option that has fewer side effects while maintaining excellent efficacy. The cholestanol derivative is represented by a specific formula, which includes various sugar components. Another significant patent is for an antitumor agent, which is a sugar-cholestanol compound that can be easily synthesized and demonstrates satisfactory antitumor activity. This anticancer agent contains a cholestanol compound or a cyclodextrin inclusion complexation of the compound, along with a method for treating cancer using this innovative compound.
Career Highlights
Throughout his career, Yazawa has worked with reputable organizations, including Otsuka Pharmaceutical Company, Limited and Gunma University. His experience in these institutions has contributed to his expertise in the field of pharmaceuticals and cancer research.
Collaborations
Yazawa has collaborated with notable coworkers such as Touyou Nishimura and Izumi Takai. Their joint efforts have further advanced the research and development of effective cancer treatments.
Conclusion
Shin Yazawa's contributions to cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to inspire advancements in the field of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile